-

REMINDER: Ardent Health, Inc. Investors With Significant Losses Must Act By March 9, 2026

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE:ARDT) investors of the March 9, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.

If you purchased or otherwise acquired Ardent securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your rights or interests.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of July 18, 2024 through November 12, 2025, inclusive (“the Class Period”). The lawsuit alleges that Ardent stated it employed an active monitoring process to determine the collectability of its accounts receivable, which included detailed reviews of historical collections as a primary source of information. In truth, however, Ardent did not primarily rely on detailed reviews of historical collections when determining the collectability of its accounts receivable, but instead utilized a 180-day cliff, at which point an account became fully reserved. This practice allowed Ardent to report higher amounts of accounts receivable during the Class Period and delay recognizing losses on uncollectable accounts.

On November 12, 2025, Ardent issued a press release announcing its financial results for the third quarter of 2025. In connection with that release, the Company disclosed that it recorded a $43 million reduction in revenue due to a change in accounting estimates regarding the collectability of accounts receivable. Ardent also revealed a $54 million increase to its professional liability reserves related to claims arising in New Mexico. On this news, the price of Ardent shares declined by $4.75 per share, or approximately 33.8%, from $14.05 per share on November 12, 2025 to close at $9.30 on November 13, 2025.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Ardent securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

Kirby McInerney LLP

NYSE:ARDT

Release Versions

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

More News From Kirby McInerney LLP

SPORTRADAR GROUP AG INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Sportradar Group AG (“Sportradar” or the “Company”) (NASDAQ:SRAD). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 22, 2026, Muddy Waters Research published a report alleging, among other things, that Sp...

NANO-X IMAGING LTD. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ:NNOX). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 20, 2026, Nano-X announced its fourth quarter 2025 financial results. Among other items, Nan...

ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until May 29, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this de...
Back to Newsroom